The vaccine given to the 45 years man at the emergency room is to protect him. The laceration is a port of entry to germs. The patient will receive the tetanus toxoid to protect him. Tetanus toxin is a powerful neurotoxin that can affect severely the patient because he has not received the vaccine and as a result his immune system may be compromised. In his case, his immune system needs to make antibodies, we called it active immunity. Active immunity is exposure to antigen. It is an adaptive response of the body and it is categorized as acquired or natural. By contrast the passive immunity is the presence of the antibody IgG to defend the body against invaders for a short time said an expert in occupation; medicine. “Patient will receive human immunoglobulin because of his wound and because he has never been vaccinated” (Oxford Journal, Occupational medicine).
The patient …show more content…
The two types are presented by Baxter (2007) “Following deep subcutaneous/intramuscular (SC/IM) administration of tetanus vaccine, the toxoid molecules are taken up at the vaccination site by immature dendritic cells: within this cell, they are processed through the endosomal pathway (involving the phagolysosome) where they are bound to major histocompatibility complex type II (MHC II) molecules; the MHC II: toxoid complex then migrates to the cell surface. While this process is happening within the cell, the now activated mature dendritic cell migrates along lymph channels to the draining lymph node where they encounter naïve T helper type 2 cells (TH2), each with their own unique-cell receptor (TCR). Identifying and then binding of the MHC II: toxoid to the specific TH2 receptor then activates the naive T cell, causing it to proliferate. Simultaneously, toxoid molecules not taken up by dendritic cells pass along lymph channels to
The patient …show more content…
The two types are presented by Baxter (2007) “Following deep subcutaneous/intramuscular (SC/IM) administration of tetanus vaccine, the toxoid molecules are taken up at the vaccination site by immature dendritic cells: within this cell, they are processed through the endosomal pathway (involving the phagolysosome) where they are bound to major histocompatibility complex type II (MHC II) molecules; the MHC II: toxoid complex then migrates to the cell surface. While this process is happening within the cell, the now activated mature dendritic cell migrates along lymph channels to the draining lymph node where they encounter naïve T helper type 2 cells (TH2), each with their own unique-cell receptor (TCR). Identifying and then binding of the MHC II: toxoid to the specific TH2 receptor then activates the naive T cell, causing it to proliferate. Simultaneously, toxoid molecules not taken up by dendritic cells pass along lymph channels to